SCHEDULE DETAILS Event Schedules
-
Breast cancer
-
9:00-09:45
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BCModerator: Shereef Elsamany
Panel:
-
09:45 –10:30
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:Dr. Meteeb Alfohaidi
Panel:
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
-
10:30-11:00
Satellite Symposium
-
8:30-9:00
Setting-up clinical trials in Middle east: Challenges and opportunities
Moderators:
Dr. Emad Tashkandi Dr. Hosam Alghanmi
Panel:
-
09:00-09:45
Pancreatic cancer
- Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
- Best neoadjuvant strategy
- 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
- biomarkers for metastatic patients
Moderator: Dr. Abdullah Alsharm
Panel:
-
09:45-10:30
Biliary tract cancer
- Immunetherapy in advanced BTC: Yes/No
- Which agent?
- Patient selection/tumour location?
- Role of maintenance therapy?
- Role of liquid biopsy/biomarker assessment
Moderator: Dr. Mohammed Algarni
panel:
-
10:30-10:45
Break